We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准了vepdegestrant——首个针对ESR1突变乳腺癌的PROTAC降解剂。了解它如何摧毁耐药性以及治疗将发生哪些变化。详情请见此处。
